Riluzole

Generic Name: Riluzole

Brand Names: Exservan, Rilutek, Tiglutik, Riluzole Zentiva

Drug Type: Small Molecule

Chemical Formula: C_₈H_₅F_₃N_₂OS

CAS Number: 1744-22-5

Unique Ingredient Identifier: 7LJ087RS6F

Background: A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.

Indication: For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)

Associated Conditions: Amyotrophic Lateral Sclerosis (ALS)

Associated Therapies: -

Clinical Trials

Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS

Phase 1

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Biological: Lenzumestrocel
Drug: Riluzole

First Posted Date: 2024-11-06

Last Posted Date: 2024-11-06

Lead Sponsor: Corestemchemon, Inc.

Target Recruit Count: 8

Registration Number: NCT06676423

Locations: 🇰🇷
Hanyang university hospital, Seoul, Korea, Republic of

Repurposing Riluzole for Cancer-Related Cognitive Impairment: a Pilot Trial

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Riluzole
Drug: Placebo

First Posted Date: 2024-08-30

Last Posted Date: 2024-12-06

Lead Sponsor: University of California, Irvine

Target Recruit Count: 34

Registration Number: NCT06580002

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California, United States

The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia

Early Phase 1

Recruiting

Conditions: Treatment-resistant Schizophrenia
Treatment-responsive Schizophrenia
Healthy Controls

Interventions: Drug: Riluzole

First Posted Date: 2024-02-21

Last Posted Date: 2024-03-05

Lead Sponsor: King's College London

Target Recruit Count: 288

Registration Number: NCT06270108

Locations: 🇬🇧
Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom

Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Phase 1

Active, not recruiting

Conditions: Stage IVA Colorectal Cancer AJCC v8
Stage IVB Colorectal Cancer AJCC v8
Stage IVC Colorectal Cancer AJCC v8
Metastatic Colorectal Carcinoma
Stage IV Colorectal Cancer AJCC v8

Interventions: Biological: Bevacizumab
Drug: Fluorouracil
Drug: Leucovorin Calcium
Drug: Oxaliplatin
Drug: Riluzole

First Posted Date: 2021-02-21

Last Posted Date: 2024-05-16

Lead Sponsor: Ning Jin

Target Recruit Count: 13

Registration Number: NCT04761614

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS

Phase 3

Active, not recruiting

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Biological: Lenzumestrocel
Drug: Riluzole
Drug: Placebo Comparator

First Posted Date: 2021-02-09

Last Posted Date: 2024-10-03

Lead Sponsor: Corestemchemon, Inc.

Target Recruit Count: 115

Registration Number: NCT04745299

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷
Pusan National University Yangsan Hospital, Yangsan, Kyungsangnam-do, Korea, Republic of

and more 2 locations

Riluzole Effects on Hippocampus Biomarkers

Early Phase 1

Completed

Conditions: Posttraumatic Stress Disorder

Interventions: Drug: Riluzole

First Posted Date: 2020-11-16

Last Posted Date: 2020-11-16

Lead Sponsor: Mclean Hospital

Target Recruit Count: 20

Registration Number: NCT04630444

Locations: 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States

Treatment of Intravenous Infusion Plasma in Amyotrophic Lateral Sclerosis

Early Phase 1

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Riluzole
Biological: Plasma from healthy young people treatment + Riluzole

First Posted Date: 2020-07-02

Last Posted Date: 2020-07-07

Lead Sponsor: Peking University Third Hospital

Target Recruit Count: 20

Registration Number: NCT04454840

Locations: 🇨🇳
Peking University Third Hospital, Beijing, China

Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.

Phase 2

Suspended

Conditions: Oxaliplatin-induced Peripheral Neuropathy

Interventions: Drug: Placebo Oral Tablet
Drug: Riluzole

First Posted Date: 2018-10-29

Last Posted Date: 2024-11-04

Lead Sponsor: UNICANCER

Target Recruit Count: 80

Registration Number: NCT03722680

Locations: 🇫🇷
CHU de Clermont -Ferrand, Clermont-Ferrand, France
🇫🇷
ICO - Site Paul Papin, Angers, France
🇫🇷
CH Beauvais, Beauvais, France

and more 13 locations

Riluzole in Patients With Spinocerebellar Ataxia Type 7

Phase 2

Recruiting

Conditions: SCA7

Interventions: Drug: Riluzole
Drug: Placebo

First Posted Date: 2018-09-07

Last Posted Date: 2024-12-02

Lead Sponsor: S. Andrea Hospital

Target Recruit Count: 34

Registration Number: NCT03660917

Locations: 🇮🇹
Neurological Unit, S. Andrea Hospital, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Rome, Italy

Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)

Conditions: ALS
Amyotrophic Lateral Sclerosis
Lou Gehrig Disease
Lou Gehrig's Disease
Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Lou-Gehrigs Disease

First Posted Date: 2018-05-25

Last Posted Date: 2019-07-26

Lead Sponsor: Biohaven Pharmaceuticals, Inc.

Registration Number: NCT03537807

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy